Please find attached the outcome of the Board Meeting and the EGM date.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Asston Pharmaceuticals held a board meeting on 30th March 2026 and approved three key leadership changes effective the same day. Mr. Sumit Pawar, a commerce graduate with around 3 years of experience in finance and accounting, has been appointed as the new Chief Financial Officer. Mr. Yashvardhan Tupe, with a background in mechanical engineering and international business management, joins as an Additional Non-Executive Director. Mr. Sandip Sharma, a qualified Company Secretary who has cleared the Independent Director Examination from IICA, has been appointed as an Additional Non-Executive Independent Director. None of the three appointees are related to existing directors on the board. The board also approved convening an Extraordinary General Meeting (EGM) on 28th April 2026 at 12:30 PM via video conferencing.
The simultaneous appointment of a new CFO and two new directors, followed by an EGM within a month, suggests the company is undergoing governance restructuring and may table significant resolutions for shareholder approval. Retail investors should watch for the EGM notice and agenda to understand what these leadership changes are setting up.